THE PAST, PRESENT AND FUTURE OF OUR GLOBAL THROMBOSIS REGISTRIES

STUDY ATTRIBUTES

- **Garfield**
  - 57,262 patients enrolled
  - 35 countries
  - 1,352 sites
  - 5 sequential prospective cohorts
  - Long-term follow-up (2-8 years after diagnosis)
  - Study end February 2019

- **River**
  - 10,870 patients enrolled
  - 28 countries
  - 417 sites
  - 2 sequential prospective cohorts
  - Long-term follow-up (minimum 3 years after diagnosis)
  - Study end April 2020

- **Ongoing**
  - 5,072 patients enrolled
  - 17 countries
  - 306 sites
  - Ongoing follow-up
  - Study end September 2019

ACHIEVEMENTS AND ADVANCES

- **Garfield**
  - The largest global prospective AF registry
  - First AF risk score assessing stroke, bleeding and mortality in a single tool using machine learning
  - Examines treatment effects of VKAs and NOACs

  - Study design helps understanding of which therapies are being used for which patients
  - Representative of real-life treatment practices in different countries and care settings
  - 3 year follow-up data allows long-term prospective review of recurrent VTE, PTS, CTEPH, bleeding

- **River**
  - Focuses on a single drug to study drug-specific usage patterns and dosing decisions
  - Availability of laboratory test results, e.g. SCR, Hb, RBC, WBC
  - Wide geographic variation for a drug-specific registry

  - Helps us understand reasons for anticoagulation cessation and barriers to continuation
  - Allows understanding of patterns and consequences of off-label NOAC dosing

ONGOING OUTPUTS

- Congress presentations
- Publications
- Evolving RWE quality standards
- Implementation of novel statistical methods e.g. AI and machine learning
- Clinical insights
- Patient reported outcomes
- Prescribing intelligence
- Data mining and analysis
- Partnership opportunities
- Research network
- Risk tools
- Editorial and social media content

Follow us: @TRI_Thrombosis @GARFIELD_reg